Recurrent, refractory, metastatic and/or unresectable pediatric sarcomas: Treatment options for young people 'off the roadmap'

Pediatric Health

Volumn 2, Issue 5, 2008, Pages 605-615

  Anderson, Pete ^a   Kornguth, David ^a,b   Ahrar, Kamran ^a,b   Hughes, Dennis P ^a   Phan, Phil ^a,c   Huh, Winston ^a   Cornelius, Kathleen ^a   Mahajan, Anita ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Department of Radiation Oncology ^*

^c Department of Anesthesia

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MESNA; METHOTREXATE; POLONESETRON; SEROTONIN ANTAGONIST; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ALOPECIA; BEDTIME DOSAGE; BLADDER DISEASE; BLADDER TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILDHOOD CANCER; CRYOABLATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EWING SARCOMA; EXTERNAL BEAM RADIOTHERAPY; FAMILY CENTERED CARE; HEMORRHAGIC CYSTITIS; HUMAN; INTERMETHOD COMPARISON; INTERVENTIONAL RADIOLOGY; METASTASIS; MORNING DOSAGE; NAUSEA; NEPHROTOXICITY; OSTEOSARCOMA; PATIENT ATTITUDE; PATIENT CONTROLLED ANALGESIA; PHOSPHATE BLOOD LEVEL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIOFREQUENCY ABLATION; RADIOSENSITIZATION; RECURRENT CANCER; REVIEW; RHABDOMYOSARCOMA; SARCOMA; TASK PERFORMANCE; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; VOMITING;

EID: 57549095740     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/17455111.2.5.605     Document Type: Review

References (79)

1. Herzog CE: Overview of sarcomas in the adolescent and young adult population. J. Pediatr. Hematol. Oncol. 27, 215-218 (2005).
2. Anderson PM, Pearson M: Novel therapeutic approaches in pediatric and young adult sarcomas. Curr. Oncology Reports 8, 310-315 (2006).
3. Anderson P: Osteosarcoma relapse: expect the worst, but hope for the best. Pediatr. Blood Cancer 47, 231-238 (2006).
4. Anderson P, Salazar-Abshire M: Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives. Curr. Oncology Reports 8, 415-422 (2006).
5. DeLaney TF, Trofimov AV, Engelsman M, Suit HD: Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 12, 27-35 (2005).
6. Paulino AC, Nguyen TX, Mai WY, Teh BS, Wen BC: Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. Pediatr. Blood Cancer 49, 145-148 (2007).
7. Jebsen NL, Trovik CS, Bauer HC et al.: Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian Sarcoma Group Study. Int. J. Radiat. Oncol. Biol. Phys. (2008).
8. Patel S, Delaney TF: Advanced-technology radiation therapy for bone sarcomas. Cancer Control 15, 21-37 (2008).
9. Machak GN, Tkachev SI, Solovyev YN et al.: Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin. Proc. 78, 147-155 (2003).
10. Dincbas FO, Koca S, Mandel NM et al.: The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. Int. J. Radiat. Oncol. Biol. Phys. 62, 820-828 (2005).
11. Mahajan A, Woo S, Kornguth D et al.: Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Ped. Blood Cancer (2008).
12. Anderson PM: Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin. Proc. 78, 145-146 (2003).
13. Anderson P, Aguilera D, Pearson M, Woo S: Outpatient chemotherapy + radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 15, 38-46 (2008).
14. Mahajan A, Woo SY, Kornguth DG et al.: Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr. Blood Cancer 50, 976-982 (2008).
15. Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP: Pooled analysis of Phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J. Clin. Oncol. 24, 3415-3422 (2006).
16. Ruble K, Kelly KP: Radiation therapy in childhood cancer. Seminars in Oncology Nursing 15, 292-302 (1999).
17. Thomas KE, Parnell-Parmley JE, Haidar S et al.: Assessment of radiation dose awareness among pediatricians. Ped. Radiol. 36, 823-832 (2006).
18. 153SM-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Exp. Rev. Anticancer Ther. 7, 1517-1527 (2007).
19. Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F: Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95, 2202-2210 (2002).
20. Blagosklonny MV: Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4, 1693-1698 (2005).
21. Cox JD: Chemoradiation for malignant epithelial tumors. Cancer Radiother. 2, 7-11 (1998).
22. Bentzen SM, Trotti A: Evaluation of early and late toxicitles in chemoradiation trials. J. Clin. Oncol. 25, 4096-4103 (2007).
23. Maki RG: Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. The Oncologist 12, 999-1006 (2007).
24. Leu KM, Ostruszka LJ, Shewach D et al.: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol. 22, 1706-1712 (2004).
25. Anderson P, Kopp L, Anderson N et al.: Novel bone cancer drugs: investigational agents and control paradigms for bone sarcomas. Curr. Opin. Investigational Drugs (2008).
26. Wagner LM, McAllister N, Goldsby RE et al.: Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr. Blood Cancer 48, 132-139 (2007).
27. Wagner LM, Crews KR, Iacono LC et al.: Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin. Cancer Res. 10, 840-848 (2004).
28. Kushner BH, Kramer K, Modak S, Cheung NK: Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J. Clin. Oncol. 24, 5271-5276 (2006).
29. Chakravarti A, Erkkinen MG, Nestler U et al.: Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin. Cancer Res. 12, 4738-4746 (2006).
30. Gregoire V, Hittelman WN, Rosier JF, Milas L: Chemoradiotherapy: radiosensitizing nucleoside analogues (review). Oncol. Rep. 6, 949-957 (1999).
31. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS: Radiosensitization by gemcitabine. Oncology (Huntingt). 13, 55-60 (1999).
32. Le Deley MC, Guinebretiere IM, Gentet JC et al.: SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur. J. Cancer 43, 752-761 (2007).
33. Anderson P: Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible. Nature Clinical Practice 4, 624-625 (2007).
34. Aguilera D, Hayes-Jordan A, Anderson P, Woo S, Pearson M, Green H: Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor. Sarcoma id 261589 (2008).
35. Klingebiel T, Boos J, Beske F et al.: Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr. Blood Cancer 50, 739-745 (2008).
36. Findlay M, von Minckwitz G, Wardley A: Effective oral chemotherapy for breast cancer: pillars of strength. Ann. Oncol. (2007).
37. Ferrari A, Grosso F, Stacchiotti S et al.: Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. Pediatr. Blood Cancer 49, 864-866 (2007).
38. Reidy DL, Chung KY, Timoney JP et al.: Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J. Clin. Oncol. 25, 2691-2695 (2007).
39. Casanova M, Ferrari A, Bisogno G et al.: Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101, 1664-1671 (2004).
40. Kebudi R, Gorgun O, Ayan I: Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr. Blood Cancer 42, 320-324 (2004).
41. Chamberlain MC, Kormanik PA: Chronic oral VP-16 for recurrent medulloblastoma. Pediatric Neurology 17, 230-234 (1997).
42. Skubitz KM, Hamdan H, Thompson RC Jr: Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 72, 2963-2969 (1993).
43. Chang VT, Sorger B, Rosenfeld KE et al.: Pain and palliative medicine. Journal of rehabilitation research and development, 44, 279-294 (2007).
44. Shevah O, Laron Z: Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm. IGF Res. 17, 54-57 (2007).
45. Savage SA, Woodson K, Walk E et al.: Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol. Biomarkers Prev. 16, 1667-1674 (2007).
46. Zhou Z, Bolontrade MF, Reddy K et al.: Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin. Cancer Res. 13, 4867-4873 (2007).
47. Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES: VEGF(165) expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis (2008).
48. Shor AC, Agresta SV, D'Amato GZ, Sondak VK: Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 15, 47-54 (2008).
49. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G: Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life sciences 68, 109-117 (2000).
50. Boddy AV, English M, Pearson AD, Idle IR, Skinner R: Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur. J. Cancer 32A, 1179-1184 (1996).
51. Skinner R: Chronic ifosfamide nephrotoxicity in children. Med. Ped. Oncol. 41, 190-197 (2003).
52. Lemieux J, Maunsell E, Provencher L: Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology (2007).
53. Batchelor D: Hair and cancer chemotherapy: consequences and nursing care - a literature study. Eur. J. Cancer Care 10, 147-163 (2001).
54. Boyer MW, Moertel CL, Priest JR, Woods WG: Use of intracavitary cisplatin for the treatment of childhood solid tumors in the chest or abdominal cavity. J. Clin. Oncol. 13, 631-636 (1995).
55. Volker T, Denecke T, Steffen I et al.: Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J. Clin. Oncol. 25, 5435-5441 (2007).
56. Garrett KM, Fuller CE, Santana VM, Shochat SJ, Hoffer FA: Percutaneous biopsy of pediatric solid tumors. Cancer 104, 644-652 (2005).
57. Hoffer FA: Interventional radiology in pediatric oncology. Eur. J. Radiol. 53, 3-13 (2005).
58. Bittles MA, Hoffer FA: Interventional radiology and the care of the pediatric oncology patient. Surg. Oncol. 16, 229-233 (2007).
59. Ahrar K, Wallace MJ, Matin SF: Percutaneous radiofrequency ablation: minimally invasive therapy for renal tumors. Exp. Rev. Anticancer Ther. 6, 1735-1744 (2006).
60. Ahrar K: The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors. Curr. Oncologry Reports 6, 315-320 (2004).
61. Callstrom MR, Charboneau JW: Percutaneous ablation: safe, effective treatment of bone tumors. Oncology 19, 22-26 (2005).
62. Goetz MP, Callstrom MR, Charboneau JW et al.: Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J. Clin. Oncol. 22, 300-306 (2004).
63. Wang H, Littrup PJ, Duan Y, Zhang Y, Feng H, Nie Z: Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures. Radiology 235, 289-298 (2005).
64. Ahmed A, Littrup P: Percutaneous cryotherapy of the thorax: safety considerations for complex cases. Am. J. Radiol. 186, 17,03-1706 (2006).
65. Allaf ME, Varkarakis IM, Bhayani SB, Inagaki T, Kavoussi LR, Solomon SB: Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation - initial observations. Radiology 237, 366-370 (2005).
66. Carrafiello G, Lagana D, Ianniello A et al.: Post- radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works. Australasian Radiology 51, 550-554 (2007).
67. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, Abcouwer SF: Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-κB and activating protein-1. Cancer Research 64, 4858-4869 (2004).
68. Grimble RF: Immunonutrition. Curr. Opin. Gastroenterol. 21, 216-222 (2005).
69. Fuchs BC, Bode BP: Stressing out over survival: glutamine as an apoptotic modulator. J. Surg. Res. 131, 26-40 (2006).
70. Korczak DJ, Connolly B, Baron T, Katzman DK, Bernstein S: Experience with image-guided gastrostomy and gastrojejunostomy tubes in children and adolescents with primary psychiatric illness. Int. J. Eating Disorders 40, 645-651 (2007).
71. Collins JJ, Grier HE, Sethna NF, Wilder RT, Berde CB: Regional anesthesia for pain associated with terminal pediatric malignancy. Pain 65, 63-69 (1996).
72. Culp WC, Payne MN, Montgomery ML: Thoracic paravertebral block for analgesia following liver mass radiofrequency ablation. The Br. J. Radiol. 81, E23-25 (2008).
73. Charon R: Narrative and medicine. New Engl. J. Med. 350, 862-864 (2004).
74. Harter LM, Japp PM: Technology as the representative anecdote in popular discourses of health and medicine. Health Communication 13, 409-425 (2001).
75. Harter LM, Japp PM, Beck CS: Narratives, Health and Healing. Lawrence Erlbaum Associates, PA, USA (2005).
76. Selzer R, Charon R: Stories for a humanistic medicine. Acad. Med. 74, 42-44 (1999).
77. Sidhu R, Passmore A, Baker D: The effectiveness of a peer support camp for siblings of children with cancer. Pedlatr. Blood Cancer 47, 580-588 (2006).
78. Norville D: Thank You Power: Making the Science of Gratitude Work for You. Thomas Nelson, Nashville, TN, USA (2007).
79. Harter L, Hayward C, Cole C: The Art of the Possible. Documentary, Communications dept, Ohio University (Athens, OH, USA) (2008).